NOI HT941026N0069 Total Parenteral Nutrition (TPN) Compounded IV Fluids V2.pdf

Notice of Intent to Sole Source

HT941026N0069

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER

CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.

The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division - West (HCD-W), Echo Branch intends to award a firm fixed price five (5)-Year Blanket Purchase Agreement (BPA) RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government’s needs, to:

CENTRAL ADMIXTURE PHARMACY SERVICES, INC.

2525 MCGAW AVE

IRVINE, CALIFORNIA 92614-5841 USA

UEI: NDPWXJSVYVH9

CAGE: 3S5G9

The North American Industry Classification System (NAICS) code for this requirement is 325412 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,300 (in number of employees).

The Product Service Code (PSC) is 6505 Drugs and Biologicals Products.

The objective of this sole source award is to procure Pre-Mixed Intravenous (IV) Fluids for Madigan Army Medical Center for injections for Nuclear Medicine Division.

Product List:

Item Description TPN Volume Qty per Month

TrophAmine® / Plenamine™ 15% 1 - 1000 mL 30

1001 - 1500 mL 15 1501 - 2000 mL 15 2001 - 2500 mL 10 2501 - 3000 mL 5 3001 mL or greater 5

Nutrilipid® 20% in 3-in-1 TPN Per 100 mL 5 SMOF Lipid in 3-in-1 TPN Per 100 mL 5 TPN Delivery Per Delivery 30

Agency and Requirement Description and Market Research Conducted:

DHA HCD-W is supporting Madigan Army Medical Center at Joint Base Lewis-McChord (JBLM) in Tacoma, WA, with a critical requirement for outsourcing pharmacy intravenous (IV) compounding services. Specifically, this requirement is for the procurement of Pre-Mixed IV Fluids, cardioplegic solutions, and specialized Total Parenteral Nutrition (TPN) solutions, including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid. Due to the exacting clinical specifications of these medical products, no substitutes are permissible. Furthermore, to support the critical and time-sensitive needs of specialized inpatient populations, the required products must be available for ordering and guaranteed same-day delivery, seven days a week.

Extensive market research was conducted in accordance with Federal Acquisition Regulation (FAR) Part 10 to determine the availability of commercial sources. A review of mandatory sources under FAR 8.002(a)(1)(i) through (iv), including Federal Prison Industries and AbilityOne, determined these avenues are not applicable. Further research into FAR 8.002(a)(1)(v) and FAR 8.003 yielded no possible sources through the General Services Administration (GSA), Federal Supply Schedules (FSS), or other mandatory sources. Broad database searches were conducted across FPDS-NG, GSA Advantage, GSA eLibrary, GSA Global Supply, NASA SEWP, and VA FSS using keywords such as “Pre-Mixed IV Fluids” and “Central Admixture.” These searches either yielded zero results or failed to identify contractors capable of providing the exact or equal supplies required. Additionally, a review of internal contracting activity via the BPA Tracker revealed no similar contracts currently in place to leverage. Open market research, including internet searches and personal telephone contacts with potential vendors, confirmed that while "Pre-Mixed IV Fluids" are commercially available per FAR 8.004 and FAR 12.1, only Central Admixture Pharmacy Services, Inc. (CAPS) can meet the agency's strict delivery and formulary requirements.

Delivery location:

Madigan Army Medical Center, Department of Pharmacy Attn: Pharmacy Support / Holly Heatherly BLDG 9040A Fitzsimmons Drive Tacoma, WA 98431

Estimated Delivery Schedule: 1 October 2026 to 30 September 2031 (Including 12 months and four (4) 12 months options year).

Based on market research and previous acquisition history, it has been determined that Central Admixture Pharmacy Services (CAPs), Inc, is the only source that can meet the Government’s minimum requirements to provide Pre-Mixed Intravenous (IV) Fluids for Madigan Army Medical Center.

This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required Pre-Mixed Intravenous (IV) Fluids for Madigan Army Medical Center. Capability statements shall not exceed two

(2) (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.

If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Contract Specialist at Cha-on P. Gordon cha-on.p.gordon2.civ@health.mil at and Contracting Officer at Mariangela Monsalve mariangela.j.monsalve.civ@health.mil. The closing date for challenges is no later than 10:00 a.m.

(Pacific), Tuesday June 30, 2026.

NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.

mailto:cha-on.p.gordon2.civ@health.mil mailto:cha-on.p.gordon2.civ@health.mil mailto:mariangela.j.monsalve.civ@mail.mil

The objective of this sole source award is to procure Pre-Mixed Intravenous (IV) Fluids for Madigan Army Medical Center for injections for Nuclear Medicine Division.